A Randomized Phase 2 Trial of Bortezomib--Dexamethasone Versus Bortezomib--Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib--Dexamethasone Administered as Second-Line Treatment.
A Randomized Phase 2 Trial of Bortezomib--Dexamethasone Versus Bortezomib--Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib--Dexamethasone Administered as Second-Line Treatment.
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2009
Συγγραφείς:
Dimopoulos, Meletios A Roddie, Huw Beksac, Meral Benboubker, Lotfi Jurgutis, Romualdas Langer, Christian de la Rubia, Javier Casado, Luis Felipe Kuliczkowski, Kazimierz Macukanovic-Golubovic, Lena others
